Company Profile
Verrica Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- VRCA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.36 USD (-2.72%)
Close
Last updated: August 6, 2026
99.5M USD
Market cap
Why the stock is moving
The latest monitored company update is “Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.
Company overview
Medical Dermatology
Verrica Pharmaceuticals develops and commercializes treatments for dermatologic diseases, including viral skin conditions and non-melanoma skin cancers.
YCANTH for Molluscum
YCANTH is a drug-device combination containing a controlled formulation of cantharidin in a single-use applicator. It is the first FDA-approved, healthcare-professional-administered treatment for molluscum contagiosum in adults and children two years of age and older.
Common-Wart Expansion
Verrica is evaluating YCANTH in the global pivotal COVE-2 and COVE-3 Phase 3 studies for common warts. The program is intended to extend the product into a substantially larger dermatology population.
VP-315 Skin-Cancer Program
VP-315, or ruxotemitide, is a licensed oncolytic peptide being prepared for Phase 3 development in basal cell carcinoma. The broader license also covers other non-melanoma skin cancers, including squamous cell carcinoma.
Future catalysts
Topline results from the global Phase 3 YCANTH program in common warts in mid-2027.
Recent news
- 01
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
Source: Verrica Pharmaceuticals
- 02
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
Source: Verrica Pharmaceuticals
- 03
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
Source: Verrica Pharmaceuticals
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Verrica Pharmaceuticals (VRCA)?
Verrica Pharmaceuticals (VRCA) most recently closed at 5.36 USD, a -2.72% move versus the previous session.
What is the market cap of Verrica Pharmaceuticals (VRCA)?
Verrica Pharmaceuticals currently has a market capitalization of 99.5M USD on BioPharmSignal.
What does Verrica Pharmaceuticals do?
Medical Dermatology Verrica Pharmaceuticals develops and commercializes treatments for dermatologic diseases, including viral skin conditions and non-melanoma skin cancers. YCANTH for Molluscum YCANTH is a drug-device combination containing a controlled formulation of cantharidin in a single-use applicator. It is the first FDA-approved,...
On which exchange is VRCA stock listed?
Verrica Pharmaceuticals (VRCA) is associated with NASDAQ, United States, Biopharma.
What is COVE-2?
Common-Wart Expansion Verrica is evaluating YCANTH in the global pivotal COVE-2 and COVE-3 Phase 3 studies for common warts.
Which conditions is Verrica Pharmaceuticals targeting with COVE-2?
Verrica Pharmaceuticals is associated with cancer therapeutics, dermatology based on its company overview and current catalyst commentary.
How does Verrica Pharmaceuticals describe recent progress with COVE-2?
Topline results from the global Phase 3 YCANTH program in common warts in mid-2027.
What is COVE-3?
Common-Wart Expansion Verrica is evaluating YCANTH in the global pivotal COVE-2 and COVE-3 Phase 3 studies for common warts.